Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Xiaochun Zhang, Juan Manuel O’Connor et al.|The Lancet Oncology|2023

Cited by 614